Proton Pump Inhibitors

The stomach lining holds specialized parietal cells whose only job is to pump hydrochloric acid into the stomach. Deep inside each cell sits the machine that does it: the H⁺/K⁺-ATPase, better known as the proton pump. This pump is the final common pathway for acid — no matter what stimulates the cell, acid only appears when the pump physically trades a potassium ion for a hydrogen ion (proton) and secretes it into the stomach.

Three signals switch the parietal cell on: histamine (from nearby ECL cells, acting on H2 receptors), gastrin (a hormone released when food arrives), and acetylcholine (from the vagus nerve). All three ultimately converge on activating that one pump. This is the key to understanding the whole class: because H2 blockers only block the histamine arm, acid can still be driven by gastrin and acetylcholine — but a proton pump inhibitor blocks the pump itself, so it shuts down acid regardless of which signal is firing. That is why PPIs are the most complete acid suppressors we have.

A PPI is a clever prodrug: swallowed in an enteric-coated form (so stomach acid doesn’t destroy it), it is absorbed in the small intestine, travels in the blood, and slips into the parietal cell. It only becomes active in one place — the intensely acidic secretory canaliculus right next to the pump, where acid chemically converts it into its reactive form. That form then forms a covalent, irreversible bond to the pump, permanently disabling it.

Two consequences fall out of this and explain almost everything about how PPIs are dosed. First, timing matters: the drug can only bind pumps that are *actively* pumping, and pumps are switched on by a meal — so a PPI is taken 30–60 minutes before the first meal of the day, timing the drug’s peak to the meal that activates the most pumps. Second, the effect outlasts the drug: omeprazole is gone from the blood in about an hour (short half-life), yet acid suppression lasts up to ~3 days, because the cell must synthesize brand-new pump enzyme before acid secretion recovers. This is also why full clinical effect takes a few days to build — it accumulates pump by pump.

Stomach acid isn’t only about digestion — it is a barrier and a helper, and removing it for months is what drives the long-term concerns. Acid kills swallowed microbes, so profound suppression is associated with C. difficile diarrhea and enteric infections. Acid and pepsin cleave vitamin B12 and free up dietary magnesium and calcium for absorption, so long-term use is linked to B12 deficiency, hypomagnesemia (an FDA label warning — monitor magnesium on prolonged therapy), and a modest fracture signal. A distinct, idiosyncratic reaction — acute interstitial nephritis — can also occur and warrants stopping the drug.

It is worth being honest about strength of evidence: hypomagnesemia, C. difficile, and interstitial nephritis are the most solid (label warnings, causal), whereas the pneumonia and chronic-kidney-disease associations are weaker and likely confounded. There is also a pharmacologic rebound: chronically low acid raises gastrin, which over time enlarges the acid-making cells — so when a long-term PPI is stopped abruptly, acid can surge above baseline for a few weeks, mimicking a relapse. That is why prolonged courses are tapered, and why the guiding principle is the lowest effective dose for the shortest necessary time. Reassuringly, PPIs carry no boxed warning.